See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no evidence to suggest that the MMR (measles, mumps, and rubella) vaccine is unsafe when administered in conjunction with Cosentyx (secukinumab). However, it is always important to consult with a healthcare provider before receiving any vaccinations or medications.

According to the Centers for Disease Control and Prevention (CDC), "Live vaccines are generally not recommended for people with weakened immune systems because they may not provide adequate protection and could cause severe infections." Cosentyx is a medication used to treat several autoimmune conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by targeting a specific protein in the body's immune system, which may affect the body's ability to respond to vaccines.

The MMR vaccine is a live vaccine, which means it contains a weakened form of the measles, mumps, and rubella viruses. While the vaccine can cause mild side effects, such as fever or mild rash, it is generally safe and effective at preventing these diseases. However, people with weakened immune systems may not respond as well to the vaccine and may be at risk for more severe side effects.

DrugPatentWatch.com, a website that provides information on drug patents and FDA approvals, does not have any specific information on the safety or efficacy of administering the MMR vaccine with Cosentyx.

In summary, while there is no evidence to suggest that the MMR vaccine is unsafe when administered with Cosentyx, it is important to consult with a healthcare provider before receiving any vaccinations or medications. People with weakened immune systems, such as those taking Cosentyx, may not respond as well to live vaccines and may be at risk for more severe side effects.

Sources:

* Centers for Disease Control and Prevention. (2021). Live Vaccines and People with Weakened Immune Systems. <https://www.cdc.gov/vaccines/adults/rec-vac/people-with-weakened-immune-systems.html>.
* DrugPatentWatch.com. (n.d.). Secukinumab. <https://www.drugpatentwatch.com/drugs/secukinumab>.
* U.S. Food and Drug Administration. (2016). Cosentyx (secukinumab) Prescribing Information. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125557s000lbl.pdf>.